NL
DE
Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders
Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. The partnership aims to accelerate the development of a diagnostic technology platform that improves the standard of care for patients with bleeding disorders.
Enzyre was founded in 2016 with the mission to save patients from bleeding to death with their Enzypad technology. Their vision is to create a point of care diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.
Read the Takeda announcement here: https://lnkd.in/dJSqpRk
Related news items
Third Radboudumc Investment Day again well-attended
16 October 2023On October 12, the Radboudumc Investment Day took place for the third time. Scientists, entrepreneurs and investors from the life sciences & health sector came together in the Radboudumc Experience Center to exchange knowledge, network and talk about new collaborations.
read more
Take Off 2 funding from NWO for Predica Diagnostics
30 June 2023Predica Diagnostics just secured the Take Off 2 funding to accelerate development of their cervical (pre)cancer prediction test.
read more
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
Meet Healthy Ideas, Healthy Returns
2 June 2023Do you have a golden idea to improve healthcare, but not the resources to realize it? Discover Healthy Ideas, Healthy Returns: a Benelux-wide public-private network offering opportunities for healthcare investments and propositions, among other things.
read moreAftermovie Investment Day 2022 and a new date for 2023!
13 December 2022Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read moreEnzyre closes Series A financing round of €12M to advance pioneering diagnostic technology platform for hemophilia patients
2 November 2022Enzyre has announced that it has successfully raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment, Takeda Ventures, and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.
read more